5WB8

Crystal structure of the epidermal growth factor receptor extracellular region in complex with epigen


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3 Å
  • R-Value Free: 0.312 
  • R-Value Work: 0.265 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Freed, D.M.Bessman, N.J.Kiyatkin, A.Salazar-Cavazos, E.Byrne, P.O.Moore, J.O.Valley, C.C.Ferguson, K.M.Leahy, D.J.Lidke, D.S.Lemmon, M.A.

(2017) Cell 171: 683-695.e18

  • DOI: 10.1016/j.cell.2017.09.017
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways. Using crystallography and other approaches, we show how the EGFR ligands epiregulin (ER ...

    Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways. Using crystallography and other approaches, we show how the EGFR ligands epiregulin (EREG) and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region. As a consequence, EREG or EPGN induce less stable EGFR dimers than EGF-making them partial agonists of EGFR dimerization. Unexpectedly, this weakened dimerization elicits more sustained EGFR signaling than seen with EGF, provoking responses in breast cancer cells associated with differentiation rather than proliferation. Our results reveal how responses to different EGFR ligands are defined by receptor dimerization strength and signaling dynamics. These findings have broad implications for understanding receptor tyrosine kinase (RTK) signaling specificity. Our results also suggest parallels between partial and/or biased agonism in RTKs and G-protein-coupled receptors, as well as new therapeutic opportunities for correcting RTK signaling output.


    Organizational Affiliation

    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Epidermal growth factor receptor
A, D
507Homo sapiensMutation(s): 0 
Gene Names: EGFR (ERBB, ERBB1, HER1)
EC: 2.7.10.1
Find proteins for P00533 (Homo sapiens)
Go to Gene View: EGFR
Go to UniProtKB:  P00533
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Epigen
B, C
61Homo sapiensMutation(s): 0 
Gene Names: EPGN
Find proteins for Q6UW88 (Homo sapiens)
Go to Gene View: EPGN
Go to UniProtKB:  Q6UW88
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
MAN
Query on MAN

Download SDF File 
Download CCD File 
D
ALPHA-D-MANNOSE
C6 H12 O6
WQZGKKKJIJFFOK-PQMKYFCFSA-N
 Ligand Interaction
BMA
Query on BMA

Download SDF File 
Download CCD File 
A, D
BETA-D-MANNOSE
C6 H12 O6
WQZGKKKJIJFFOK-RWOPYEJCSA-N
 Ligand Interaction
NAG
Query on NAG

Download SDF File 
Download CCD File 
A, D
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3 Å
  • R-Value Free: 0.312 
  • R-Value Work: 0.265 
  • Space Group: P 43 2 2
Unit Cell:
Length (Å)Angle (°)
a = 104.050α = 90.00
b = 104.050β = 90.00
c = 285.940γ = 90.00
Software Package:
Software NamePurpose
HKL-3000data reduction
PDB_EXTRACTdata extraction
PHENIXrefinement
PHENIXdata scaling
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer InstituteUnited StatesR01-CA198164
National Institutes of Health/National Cancer InstituteUnited StatesU54-CA193417
National Institutes of Health/National Institute of General Medical SciencesUnited StatesT32-GM008275
National Institutes of Health/National Cancer InstituteUnited StatesR01-CA112552
National Institutes of HealthUnited StatesF32-109688

Revision History 

  • Version 1.0: 2017-10-18
    Type: Initial release
  • Version 1.1: 2017-10-25
    Type: Database references
  • Version 1.2: 2017-11-01
    Type: Database references